Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Gliadel

Bayer symbol

Bayer buys Chinese consumer care company

Acquires Dihon Pharmaceutical as Algeta takeover closes

- PMLiVE

NICE backs new use for Bayer’s Eylea

Will go up against Novartis’ Lucentis in treatment of macular oedema in UK

Novartis day

Novartis under fire in Japan over Diovan promotion

Offices raided amid investigation into falsified data

Bayer symbol

Bayer drug cuts infusion burden in haemophilia A

Able to provide longer-term protection against bleeding episodes in late-stage trial

- PMLiVE

FDA knocks back J&J and Bayer’s Xarelto in ACS

Follows unanimous negative committee vote

- PMLiVE

Germany looks again at Fycompa pricing

Eisai's epilepsy drug could be re-entered onto market

- PMLiVE

NIH forges $230m research alliance with pharma

Brings 10 pharma companies together to speed up research in Alzheimer’s, diabetes and arthritis

- PMLiVE

NICE backs Astellas’ Xtandi in prostate cancer

But company criticises restrictions imposed by HTA body for England

- PMLiVE

GSK’s diabetes drug among CHMP recommendations

EMA committee also backs drugs from Bayer, Takeda and Linepharma France

Who tops the pharma list?

Chris Ross, with the help of healthcare analysts GlobalData, takes a New Year look at the past, present and future of global pharma, and asks: what’s trending? 

- PMLiVE

Ipragliflozin beats diabetes rivals to Japanese approval

Astellas drug is first SGLT2 inhibitor backed by country’s regulator

- PMLiVE

Xarelto should not be approved in ACS says FDA panel

Advisory committee votes against new indication for Bayer and J&J’s anticoagulant

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links